New Jersey Is Suing Purdue Pharmaceutical for Hooking the Nation on Opioid Pain Killers

Arthur Sackler, Purdue Pharmaceutical, Wikipedia
  • Save
  • Save

The lawsuit says that Purdue, the makers of the painkiller OxyContin, knowingly published false information about addiction risks from its opioid medication in order to maximize sales. It says that Purdue targeted elderly and other “opioid-naive” patients. The opioid crisis in New Jersey has killed scores of people and cosy taxpayers hundreds of millions of dollars. The Sackler family which owns Purdue Pharma is listed as the 19th most wealthy family by Forbes, with $13 billion in assets. Two million people in the US are addicted to prescription drugs, and 64,070 Americans died by overdose in 2016.

Officials in New Jersey are suing one of the largest pharmaceutical companies in the U.S. over its alleged role in igniting the addiction epidemic through purposefully deceptive marketing.

New Jersey Attorney General Christopher Porrino filed a lawsuit Tuesday against Purdue Pharma. The lawsuit against Purdue, the makers of the painkiller OxyContin, will aim to refute claims made by the drug makers that these highly addictive medications are safe for treating chronic pain. Porrino says the company knowingly marketed false information about addiction risks from its opioid medication in order to maximize sales, displaying what Porrino calls a “inconceivable callousness and irresponsibility,” reports Reuters.

The suit alleges that in addition to lying to doctors and other medical professionals about the risks posed from opioid painkillers, Purdue specifically targeted elderly and other “opioid-naive” patients to push its product. Porrino says this marketing strategy ultimately led to the state’s opioid crisis, which is claiming scores of lives and costing taxpayers hundreds of millions of dollars. (RELATED: How One Painkiller Ignited The Addiction Epidemic)

A growing number of recent lawsuits allege Purdue launched a fraudulent marketing scheme to boost sales of OxyContin in the late 1990s that downplayed the risks for addiction from opioid pain medication. Officials in Tennessee, which filed a lawsuit against Purdue Pharma Sept. 29, claim the company’s tactics served as a model for other major drug makers like Endo Pharmaceuticals and Teva Pharmaceuticals to do the same thing

Purdue Pharma is owned by the Sackler family, which is listed as the 19th wealthiest family in the country on the annual Forbes list, coming in at being worth $13 billion. The family’s fortune largely comes from OxyContin sales, which their company branded and introduced as an extended release painkiller in 1995.

“I don’t know what I can say about the company except that they’ve been so careful always to keep from harming anybody,” Beverly Sackler, who is 93-years-old and the owner of Purdue Pharma, previously told

Purdue Pharma pleaded guilty in 2007 to felony charges for false marketing of OxyContin and paid $635 million as a result. The company overstated how long the effects of the medication lasted and severely downplayed the addiction risks of the drug. Three executives also pleaded guilty to criminal charges but dodged prison time.

Medical professionals say a shift in the 1990s to “institutionalize” pain management opened the doors for pharmaceutical companies to encourage the mass prescribing of painkillers by doctors, and Purdue Pharma led that effort.

Purdue Pharma denies allegations of complicity in the opioid epidemic and says they are committed to curbing rates of opioid abuse.

Read full article here…

Visit our Classified ads.

Check out our Classified ads at the bottom of this page.

Recent stories & commentary

  • Save

Biden Issues Veto to Protect Woke Leftist ESG Investing Rule

March 21, 2023 ZeroHedge 1

Consumers’ Research said, “This veto by President Biden goes directly against the interests of the American people and once again creates an illegitimate loophole for companies like BlackRock, State Street and Vanguard to exploit to put politics over profits with American pension dollars.”


For classified advertising rates and terms, click here. The appearance of ads on this site does not signify endorsement by the publisher. We do not attempt to verify the accuracy of statements made therein or vouch for the integrity of advertisers. However, we will investigate complaints from readers and remove any message we find to be misleading or that promotes anything fraudulent, illegal, or unethical.

Notify of
Inline Feedbacks
View all comments